

Supplemental Table S1. Baseline Characteristics and Infection Rate of COVID-19 according to Diabetes Status

Characteristic	1:2 PSM				1:3 PSM			
	Non-DM	DM	<i>P</i> value	ASD	Non-DM	DM	<i>P</i> value	ASD
Number	16,754	8,377			19,386	6,462		
Male sex	8,497 (50.7)	4,376 (52.2)	0.023	0.031	9,657 (49.8)	3,290 (50.9)	0.126	0.022
Age, yr			0.019				0.072	
20–29	126 (0.8)	78 (0.9)			174 (0.9)	75 (1.2)		
30–39	746 (4.5)	416 (5.0)		0.024	1,042 (5.4)	385 (6.0)		0.025
40–49	1,921 (11.5)	1,016 (12.1)		0.021	2,550 (13.2)	849 (13.1)		0.001
50–59	3,810 (22.7)	1,838 (21.9)		0.019	4,556 (23.5)	1,452 (22.5)		0.025
60–69	4,503 (26.9)	2,136 (25.5)		0.031	5,038 (26.0)	1,638 (25.4)		0.015
70–79	3,466 (20.7)	1,744 (20.8)		0.003	3,680 (19.0)	1,234 (19.1)		0.003
≥80	2,182 (13.0)	1,149 (13.7)		0.020	2,346 (12.1)	829 (12.8)		0.022
BMI, kg/m ²	24.5±3.5	24.5±3.7	0.675	0.006	24.4±3.6	24.4±3.7	0.973	0.001
Region			0.686				0.389	
Seoul	3,229 (19.3)	1,603 (19.1)		0.004	3,717 (19.2)	1,194 (18.5)		0.018
Daegu	2,126 (12.7)	1,017 (12.1)		0.008	2,462 (12.7)	804 (12.4)		0.002
Gyeonggi	3,705 (22.1)	1,879 (22.4)		0.017	4,345 (22.4)	1,444 (22.4)		0.008
Gyeongbuk	1,376 (8.2)	674 (8.1)		0.006	1,602 (8.3)	516 (8.0)		0.010
Other	6,318 (37.7)	3,204 (38.3)		0.011	7,260 (37.5)	2,504 (38.8)		0.027
SBP, mm Hg	126.1±15.1	126.1±15.1	0.857	0.002	125.5±15.1	125.4±15.1	0.799	0.004
Glucose, mg/dL	97.3±14.5	131.9±49.9	<0.001	0.941	97.0±14.3	132.2±51.6	<0.001	0.927
AST, IU/L	27.9±17.3	28.6±20.6	0.004	0.038	27.5±16.6	28.6±21.2	<0.001	0.055
ALT, IU/L	26.7±22.8	27.9±21.0	<0.001	0.055	26.4±21.9	27.9±21.1	<0.001	0.067
γ-GTP, IU/L	41.7±62.0	44.3±60.0	0.002	0.043	40.6±60.0	43.5±59.0	0.001	0.049
Low income	3,213 (19.2)	1,627 (19.4)	0.643	0.006	3,647 (18.8)	1,242 (19.2)	0.469	0.010
Smoking	2,969 (17.7)	1,515 (18.1)	0.477	0.010	3,423 (17.7)	1,147 (17.8)	0.866	0.002
Comorbidities								
Hypertension	12,348 (73.7)	6,107 (72.9)	0.176	0.018	13,488 (69.6)	4,449 (68.9)	0.272	0.016
Dyslipidemia	13,879 (82.8)	6,851 (81.8)	0.038	0.028	15,467 (79.8)	5,115 (79.2)	0.277	0.016
IHD	3,794 (22.7)	1,879 (22.4)	0.701	0.005	4,120 (21.3)	1,322 (20.5)	0.175	0.020
Stroke	1,481 (8.8)	750 (9.0)	0.766	0.004	1,531 (7.9)	528 (8.2)	0.482	0.010
Asthma or COPD	5,305 (31.7)	2,571 (30.7)	0.117	0.021	5,958 (30.7)	1,940 (30.0)	0.282	0.016
Cancer	3,034 (18.1)	1,522 (18.2)	0.908	0.002	3,320 (17.1)	1,102 (17.1)	0.894	0.002
ESRD	151 (0.9)	76 (0.9)	0.962	0.001	149 (0.8)	47 (0.7)	0.741	0.005
CCI score	4.1±2.0	4.1±2.0	0.230	0.016	3.9±2.0	3.9±2.0	0.855	0.003
Medication								
ACEi	147 (0.9)	85 (1.0)	0.283	0.014	153 (0.8)	65 (1.0)	0.099	0.023
ARB	3,108 (18.6)	1,548 (18.5)	0.890	0.002	3,189 (16.5)	1,098 (17.0)	0.311	0.015
Steroid	3,863 (23.1)	1,905 (22.7)	0.574	0.008	4,364 (22.5)	1,444 (22.4)	0.783	0.004
Immunosuppressant	295 (1.8)	160 (1.9)	0.403	0.011	312 (1.6)	113 (1.8)	0.446	0.011
COVID-19	529 (3.2)	343 (4.1)	<0.001	0.050	630 (3.3)	268 (4.2)	0.001	0.048

Values are expressed as number (%) or mean±standard deviation. Statistical analyses were performed using *t* test or chi-squared test. Groups with and without diabetes were compared using 1:1 propensity score matching with variables including sex, age, region, BMI, low income, smoking, SBP, AST, ALT, γ-GTP, hypertension, dyslipidemia, IHD, stroke, asthma or COPD, cancer, ESRD, CCI score, ACEi, ARB, steroids, and immunosuppressants. COVID-19, coronavirus disease 2019; PSM, propensity score matching; DM, diabetes mellitus; ASD, absolute standardized mean difference; BMI, body mass index; SBP, systolic blood pressure; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GTP, gamma-glutamyltransferase; IHD, ischemic heart disease; COPD, chronic obstructive pulmonary disease; ESRD, end-stage renal disease; CCI, Charlson Comorbidity Index; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker.